Cormorant Asset Management, LP - Mar 14, 2023 Form 4 Insider Report for Ambrx Biopharma Inc. (AMAM)

Role
10%+ Owner
Signature
/s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, its General Partner, By: Bihua Chen, Managing Member
Stock symbol
AMAM
Transactions as of
Mar 14, 2023
Transactions value $
$10,211,400
Form type
4
Date filed
3/16/2023, 06:04 PM
Previous filing
Mar 13, 2023
Next filing
Apr 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMAM Ordinary Shares Purchase $2.49M +250K +0.48% $9.95 52.8M Mar 14, 2023 See Footnotes F1, F2, F3
transaction AMAM Ordinary Shares Purchase $2.65M +250K +0.47% $10.60 53M Mar 15, 2023 See Footnotes F2, F4, F5
transaction AMAM Ordinary Shares Purchase $5.07M +500K +0.94% $10.15 53.5M Mar 16, 2023 See Footnotes F2, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average sale price of American Depository Shares ("ADS") purchased in a series of open market transactions on the transaction date at prices ranging from $9.12 to $10.66 per ADS. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ADS purchased at each price. All of these ADS were purchased by the Master Fund (as defined below).
F2 Information reported herein relates to ordinary shares represented by ADS owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund III, LP ("Fund III"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund III. Cormorant Global Healthcare GP, LLC ("GP LLC") and Cormorant Private Healthcare GP III, LLC ("GP III") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the ordinary shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
F3 Represents (i) 43,021,365 ordinary shares beneficially owned by the Master Fund and (ii) 9,728,635 ordinary shares beneficially owned by Fund III.
F4 Represents the weighted average sale price of ADS purchased in a series of open market transactions on the transaction date at prices ranging from $10.295 to $11.045 per ADS. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ADS purchased at each price. All of these ADS were purchased by the Master Fund.
F5 Represents (i) 43,271,365 ordinary shares beneficially owned by the Master Fund and (ii) 9,728,635 ordinary shares beneficially owned by Fund III.
F6 Represents the weighted average sale price of ADS purchased in a series of open market transactions on the transaction date at prices ranging from $9.65 to $10.35 per ADS. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ADS purchased at each price. All of these ADS were purchased by the Master Fund.
F7 Represents (i) 43,771,365 ordinary shares beneficially owned by the Master Fund and (ii) 9,728,635 ordinary shares beneficially owned by Fund III.